Biocept, Inc.
BIOC
BIOC was delisted on the 24th of October, 2023.
27 hedge funds and large institutions have $4.9M invested in Biocept, Inc. in 2022 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 9 increasing their positions, 9 reducing their positions, and 7 closing their positions.
249% more call options, than puts
Call options by funds: $394K | Put options by funds: $113K
0% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 9
18% less funds holding
Funds holding: 33 → 27 (-6)
41% less capital invested
Capital invested by funds: $8.32M → $4.9M (-$3.42M)
71% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$246K |
| 2 |
Renaissance Technologies
New York
|
+$65K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$31K |
| 4 |
TMWM
Taylor & Morgan Wealth Management
Flint,
Michigan
|
+$28.8K |
| 5 |
BlackRock
New York
|
+$17.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$166K |
| 2 |
B
Bailard
Foster City,
California
|
-$152K |
| 3 |
FAG
Fortitude Advisory Group
Gig Harbor,
Washington
|
-$116K |
| 4 |
OQS
Occudo Quantitative Strategies
Fort Lauderdale,
Florida
|
-$104K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$96.7K |
BIOC Hedge Fund Activity: Q1 2022 in Review
27 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Biocept, Inc. (BIOC) for Q1 2022, worth a combined $4.9M — down 41% from $8.32M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of BIOC and 2 opened new positions — a net loss of 5 holders — while 9 trimmed existing stakes and 9 added.
The largest buyer was Bridgeway Capital Management, opening a new position worth an estimated $246K. The largest seller was Marshall Wace, cutting an estimated $166K.
- 27 institutional investors held Biocept, Inc. (BIOC) as of Q1 2022, down from 33 in Q4 2021.
- Funds reported $4.9M of Biocept, Inc. stock for Q1 2022, down 41% quarter-over-quarter.
- 2 funds opened new Biocept, Inc. positions in Q1 2022 and 7 closed out, a net change of -5 holders.
- The largest Biocept, Inc. buyer in Q1 2022 was Bridgeway Capital Management, an estimated $246K added.
- The largest Biocept, Inc. seller in Q1 2022 was Marshall Wace, an estimated $166K sold.
Based on aggregated 13F filings for Q1 2022.